Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Janssen Biotech (Details)

v3.21.2
Licensing and Other Arrangements - Janssen Biotech (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2021
Aug. 31, 2019
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Licensing and other arrangements                
Revenue from contracts with customers     $ 550 $ 200 $ 1,094 $ 753    
Janssen Biotech Inc. | License Agreement [Member]                
Licensing and other arrangements                
Cash payment received   $ 2,500            
Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events   $ 3,000            
Percentage of royalty on worldwide net sales of each product upon commercialization   0.75%            
Revenue from contracts with customers $ 500   0 $ 200 500 $ 200 $ 2,500  
Contract assets     0   0     $ 0
Contract liabilities     0   0     0
Capitalized contract costs     $ 0   $ 0     $ 0